LEGISLATURE OF THE STATE OF IDAHO
Sixty-eighth Legislature First Regular Session - 2025
IN THE SENATE
SENATE BILL NO. 1189
BY JUDICIARY AND RULES COMMITTEE
1 AN ACT
2 RELATING TO IMMUNIZATIONS; AMENDING CHAPTER 48, TITLE 39, IDAHO CODE, BY THE
3 ADDITION OF A NEW SECTION 39-4806, IDAHO CODE, TO ESTABLISH PROVISIONS
4 REGARDING LIMITATION OF DISTRIBUTION AND WAIVER OF IMMUNITY FOR CERTAIN
5 HUMAN GENE THERAPY PRODUCTS; AND DECLARING AN EMERGENCY AND PROVIDING
6 AN EFFECTIVE DATE.
7 Be It Enacted by the Legislature of the State of Idaho:
8 SECTION 1. That Chapter 48, Title 39, Idaho Code, be, and the same is
9 hereby amended by the addition thereto of a NEW SECTION, to be known and des-
10 ignated as Section 39-4806, Idaho Code, and to read as follows:
11 39-4806. LIMITATION OF DISTRIBUTION -- WAIVER OF IMMUNITY. (1)
12 Notwithstanding any provision of law to the contrary, a human gene therapy
13 product for any infectious disease indication shall not be distributed,
14 sold, or administered in this state unless the manufacturer of such human
15 gene therapy product affirmatively waives any immunity from suit for an
16 injury arising from a design defect of the human gene therapy product, in-
17 cluding immunity granted pursuant to 42 U.S.C. 300aa-1, et seq.
18 (2) A manufacturer of a human gene therapy product for any infectious
19 disease indication that is distributed, sold, or administered within this
20 state shall be deemed to have waived any immunity from suit for injuries
21 caused by a design defect of the human gene therapy product, including immu-
22 nity granted pursuant to 42 U.S.C. 300aa-1, et seq.
23 (3) For the purpose of this section, "human gene therapy product" means
24 all products that mediate their effects by transcription or translation of
25 transferred genetic material or by specifically altering human genetic se-
26 quences. Human gene therapy products include but are not limited to:
27 (a) Nucleic acids, such as plasmids and in vitro transcribed ribonu-
28 cleic acid;
29 (b) Genetically modified microorganisms, such as viruses, bacteria,
30 and fungi;
31 (c) Engineered site-specific nucleases used for human genome editing;
32 and
33 (d) Ex vivo genetically modified human cells.
34 SECTION 2. An emergency existing therefor, which emergency is hereby
35 declared to exist, this act shall be in full force and effect on and after
36 July 1, 2025.

[DELETED: EOFTESEOFIhLeFtRrSn-2NTESEBLN.1YJYADRSCNAGTOI;AGCR4,TE3,IOC,BYTNOFANWSN3,IOC,TOEHPGLNOFDNADWROFIYFRCNGETYP;ADDGANEYADPNEEDeItEdbyteLeofteSeofIN1.TtCr4,Te3,IoC,b,adteseiyadbyteantoofaNWS,tobeknadddasSn3,IoC,adtordasf.LNOFDN--WROFI.(gaypnoflwtotec,ahngettfrayisdeinslntbed,oradintsseustemrofshhetyptaywsayiyfmstfrayagfmadndtoftehngetyp,igiygdptto42U.3,ets)Amrofahngetyptfrayieinttisd,s,oradwnteslbeddtohewdayiyfmstfridbyadndtoftehngetyp,igiygdptto42U.3,ets)Frtepeoftss,"ngetyp"mlpsttmetresbytnortnodgcmlorbysyaghngcs.Hngetypsiebtaentldt)Nca,shaspsadinvotdrca)Gymdm,shasv,bdf)Edscnsudfrhngee)ExvogymdhncN2.Aneyegt,wheyishdtoe,tsatslbeinflfeadetonaday1,2]